Promising news from a European oncology meeting

Some news on lung cancer treatments from the European Society for Medical Oncology (or ESMO):

- A new immunotherapy (atezolizumab or Tecentriq) improved survival vs chemo as second-line therapy for patients with NSCLC. This drug could be FDA-approved by October 19.

- Pembrolizumab (Keytruda) improved survival vs chemo as first-line therapy in patients with NSCLC if they had high levels of the biomarker PD-L1. Pembrolizumab is already approved as second-line therapy (for NSCLC), but could be FDA-approved as first-line therapy by December 24.

Last edited by

1 Reply

  • I have been fighting lung cancer and just had my 5 year anniversary. I have had surgery, chemo, cyber knife radiation more chemo and now on Opdivo. I was diagnosed with stage 4 but it has not moved from my lungs. Prayer from so many people and my I don't give up attitude have helped me on my way. Stat positive and hopefully in the neat future they will find a cure

You may also like...